CMO Clinical Res Logistics
av Zenobe Gramme 10
Wavre, 1300 BELGIUM
Business: 32-15-459-959
Fax: 32-15-459-950
E-mail: sales@bnc-group.com
Web Site: www.bnc-group.com
Contact: Philippe Van der Hofstadt
4 bis Blvd de Stalingrad
Chotsy le Roi, 94600 FRANCE
Business: 33-14884-77-23
Fax: 33-14892-22-02
E-mail: arnaud.houlle@cemo.fr
Web Site: www.cemo.fr
Contact: Arnaud Houlle
1500 Business Park Dr
Bastrop, TX 78602
Business: 512-303-1265
Fax: 512-303-1390
E-mail: johnd@tcgsupplies.com
Web Site: www.tcgsupplies.com
Contact: John Davis
332 Santa Fe Dr Ste 110
Encinitas, CA 92024
Business: 760-943-6700
Fax: 760-632-4292
E-mail: fawad@coreorthopaedic.com
Web Site: www.coreorthopaedic.com
Contact: Farouk A. Awad
1325 Tri-State Pkwy Ste 300
Gurnee, IL 60031
Toll-free: 888-287-2722
Business: 847-855-7676
Fax: 847-855-9676
E-mail: kkelley@essentialgroupinc.com
Web Site: www.essentialgroupinc.com
Contact: Kristin Kelley
15350 Sherman Way Ste 350
Van Nuys, CA 91406
Toll-free: 800-926-1532
Business: 818-728-8877
Fax: 818-251-5300
E-mail: nguerrero@hemacare.com
Web Site: www.hemacare.com
Bayerstr 53
Munich, D 80335 GERMANY
Business: 49-89-7413930
Fax: 49-89-74139339
E-mail: info@interlab.de
Web Site: www.interlab.de
Contact: Hermann Schulz
2350 Mission College Blvd Ste 700
Santa Clara, CA 95054
Business: 408-330-9400
Fax: 408-330-9410
E-mail: rxavier@majaro.com
Web Site: www.majaro.com
Contact: Rudy Xavier
150 S Stratford Rd Ste 515
Winston-Salem, NC 27104
Business: 336-725-8623
Fax: 336-725-8673
E-mail: carissa.jones@mercodia.com
Web Site: www.mercodia.com
Contact: Carissa Jones
330 DeKalb St
Norristown, PA 19401
Business: 610-272-8660
Fax: 610-272-4604
E-mail: mikec@myoderm.com
Web Site: www.myoderm.com
Contact: Michael Cohen
220 W Harrison St
Seattle, WA 98119
Toll-free: 800-767-9151
Business: 206-298-0068
Fax: 206-298-9838
E-mail: contact@pacbio.com
Web Site: www.pacbio.com
Contact: Janice O'Connor
150-Q Executive Dr
Edgewood, NY 11717
Business: 631-242-3000
Fax: 631-242-3230
E-mail: info@qosina.com
Web Site: www.qosina.com
Contact: Peggy Wilson
3625 Buffalo Rd Ste 6
Rochester, NY 14624
Business: 585-594-7050
Fax: 585-594-7095
E-mail: kbrosius@semrock.com
Web Site: www.semrock.com
Contact: Kim Brosius
1735 Technology Dr Ste 430
San Jose, CA 95110
Toll-free: 800-797-7401
Fax: 800-797-7406
E-mail: marketing@systat.com
Web Site: www.systat.com
Contact: Nive Hasthak
Old Station Park Bldg St Johns St, Horwich
Bolton, BL6 7NY UNITED KINGDOM
Business: 44-1204-669033
Fax: 44-1204-669034
E-mail: sales@woodleyequipment.com
Web Site: www.woodleyequipment.com
Using Patient Reported Outcomes in Dermatology Trials
April 25th 2024In part 3 of this video interview with ACT editor Andy Studna, Melissa Mooney, director, eCOA sales engineering, IQVIA sheds light on the unique challenges of dermatology trials and how clinical outcome assessments can be implemented in them.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Grants Ziftomenib with Breakthrough Therapy Designation for NPM1-Mutant Acute Myeloid Leukemia
April 23rd 2024Data from the Phase Ib portion of the KOMET-001 trial showed that the once-daily oral treatment may provide a substantial improvement over available therapies for relapsed/refractory NPM1-mutant acute myeloid leukemia.